## Steroid-Sparing Strategy in Bullous Pemphigoid **Key Point:** Once a patient with bullous pemphigoid (BP) achieves good clinical response on systemic corticosteroids, steroid-sparing (immunosuppressive) agents are added to permit safe tapering and minimize long-term corticosteroid toxicity (osteoporosis, infection, metabolic syndrome, diabetes). ## Azathioprine as the Preferred Steroid-Sparing Agent **High-Yield:** Azathioprine is the **first-line steroid-sparing agent** in bullous pemphigoid according to major dermatology guidelines (British Association of Dermatologists, European Dermatology Forum) and standard references (Rook's Textbook of Dermatology, Habif's Clinical Dermatology): - **Mechanism** — Purine antagonist that inhibits DNA synthesis, suppressing T-cell and B-cell proliferation and reducing autoantibody production against BP180/BP230 - **Evidence base** — Multiple RCTs and cohort studies confirm azathioprine reduces cumulative corticosteroid dose and maintains remission in BP - **Dosing** — 1–3 mg/kg/day, adjusted based on TPMT (thiopurine methyltransferase) enzyme activity - **Established role** — Considered the standard immunosuppressive adjunct in BP when long-term steroid-sparing is required ### Azathioprine Dosing & Monitoring | Parameter | Details | |-----------|----------| | Starting dose | 1–3 mg/kg/day (TPMT-guided) | | Onset of action | 4–8 weeks | | Monitoring | TPMT genotype/phenotype before initiation; CBC, LFTs at baseline, then monthly | | Common side effects | Myelosuppression, hepatotoxicity, GI intolerance, increased infection risk | | Contraindication | TPMT deficiency (risk of severe myelosuppression); concurrent allopurinol use | **Clinical Pearl:** TPMT testing before azathioprine initiation is mandatory — patients with low or absent TPMT activity are at high risk of life-threatening myelosuppression. Dose is reduced in intermediate metabolizers. ## Comparison of Steroid-Sparing Agents in BP | Agent | Guideline Status | Onset | Key Monitoring | Notes | |-------|-----------------|-------|----------------|-------| | **Azathioprine** | **First-line** | 4–8 weeks | TPMT, CBC, LFTs | Standard of care for steroid-sparing in BP | | Mycophenolate mofetil | Second-line / alternative | 2–4 weeks | CBC, LFTs | Used when azathioprine is contraindicated or not tolerated | | Dapsone | Adjunct (mild BP) | 1–2 weeks | G6PD, CBC | Useful in mild/limited BP; not the preferred immunosuppressive steroid-sparer | | Rituximab | Refractory disease | Weeks–months | CBC, immunoglobulins | Reserved for severe, refractory BP; not first-line | **Why not Dapsone?** Dapsone has anti-inflammatory (anti-neutrophil) properties and may be useful in mild BP or as an adjunct, but it is **not** the preferred steroid-sparing immunosuppressive agent for a patient on systemic prednisolone requiring long-term steroid reduction. Major guidelines (BAD, EDF) recommend azathioprine or mycophenolate mofetil as the primary immunosuppressive steroid-sparers in BP. **Why not Rituximab?** Rituximab (anti-CD20 B-cell depletion) is reserved for severe, refractory BP not responding to conventional therapy. It is not indicated in a patient showing good clinical response to prednisolone. ## Steroid-Sparing Strategy in BP (Summary) 1. Achieve clinical control with prednisolone 0.5 mg/kg/day 2. Add **azathioprine** (after TPMT testing) as steroid-sparing agent 3. Begin gradual prednisolone taper once azathioprine takes effect (4–8 weeks) 4. Target: lowest effective prednisolone dose with azathioprine maintenance 5. Attempt slow withdrawal after sustained remission (typically 12–24 months) **High-Yield (Rook's / BAD Guidelines):** Azathioprine is the preferred first-line immunosuppressive adjunct in BP for long-term steroid-sparing. Mycophenolate mofetil is an acceptable alternative when azathioprine is contraindicated or not tolerated.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.